Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

British Journal of Clinical Pharmacology
Lauri I KajosaariPertti J Neuvonen

Abstract

Gemfibrozil markedly increases the plasma concentrations and blood glucose-lowering effects of repaglinide, but the effects of other fibrates on repaglinide pharmacokinetics are not known. Our aim was to investigate the effects of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. In a randomized, three-phase cross-over study, 12 healthy subjects received 400 mg bezafibrate, 200 mg fenofibrate or placebo once daily for 5 days. On day 5, a single 0.25 mg dose of repaglinide was ingested 1 h after the last pretreatment dose. The concentrations of plasma repaglinide, bezafibrate and fenofibrate and blood glucose were measured up to 7 h postdose. During the bezafibrate and fenofibrate phases, the total area under the concentration-time curve [AUC(0, infinity )] of repaglinide was 99% (95% confidence interval of the ratio to the control phase 73, 143%) and 99% (85, 127%) of the corresponding value during the placebo (control) phase, respectively. Bezafibrate and fenofibrate had no significant effect on the peak concentration (Cmax) of repaglinide. The mean half-life of repaglinide was 1.3 h in all phases. The blood glucose-lowering effect of repaglinide was not affected by bezafibrate or fenofib...Continue Reading

References

Aug 1, 1979·European Journal of Clinical Pharmacology·U AbshagenH Stork
Feb 1, 1990·Diabetes Care·A Garg, S M Grundy
Dec 13, 1996·Journal of Chromatography. B, Biomedical Applications·L D MasnattaJ P Werba
Sep 29, 1999·European Journal of Clinical Pharmacology·P N van HeiningenJ H Jonkman
Sep 8, 2000·Clinical Pharmacology and Therapeutics·J T BackmanP J Neuvonen
Sep 8, 2000·Clinical Pharmacokinetics·W Mück
May 12, 2001·Diabetes Care·W C DuckworthUNKNOWN VA Diabetes Trial
May 24, 2001·Clinical Pharmacology and Therapeutics·C KyrklundP J Neuvonen
May 23, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xia WenPertti J Neuvonen
May 22, 2002·JAMA : the Journal of the American Medical Association·Joshua A BeckmanPeter Libby
Jun 5, 2002·Atherosclerosis. Supplements·Marja-Riitta Taskinen
Jun 27, 2002·Clinical Pharmacokinetics·Vibeke Hatorp
Sep 12, 2002·Acta Diabetologica·M R Taskinen
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontJiunn H Lin
Nov 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jun-Sheng WangPertti J Neuvonen
Dec 24, 2002·Clinical Pharmacology and Therapeutics·Janne T BackmanPertti J Neuvonen
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Carl KyrklundPertti J Neuvonen
Jul 10, 2003·British Journal of Clinical Pharmacology·Thomayant PrueksaritanontNathan Yu
Aug 16, 2003·British Journal of Clinical Pharmacology·Tanja Busk BidstrupKristian Tage Hansen
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Mikko NiemiPertti J Neuvonen
Mar 18, 2004·British Journal of Clinical Pharmacology·Mikko NiemiPertti J Neuvonen

❮ Previous
Next ❯

Citations

Oct 10, 2007·The Pharmacogenomics Journal·C Rodríguez-AntonaM Ingelman-Sundberg
Jun 17, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Gillian M Keating
Sep 29, 2011·Drugs·Kate McKeage, Gillian M Keating
Nov 13, 2014·Expert Opinion on Therapeutic Targets·Katarzyna PiwowarczykJarosław Czyż
Apr 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Andreas Holstein, Winfried Beil
Nov 17, 2012·Expert Opinion on Drug Metabolism & Toxicology·Andreas HolsteinPeter Kovacs
Sep 24, 2005·Basic & Clinical Pharmacology & Toxicology·Lauri I KajosaariJanne T Backman
Aug 23, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Akira HondaYasushi Matsuzaki
Dec 1, 2005·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M YamazakiJ H Lin
Jul 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Mar 28, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Carolina SällAleksandra Galetin
Sep 6, 2018·Therapeutic Advances in Endocrinology and Metabolism·Naina Mohamed Pakkir MaideenKumar Balasubramanian
Mar 11, 2017·Orphanet Journal of Rare Diseases·Yan HuangZaza Khuchua
Jun 21, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
May 29, 2015·Expert Review of Clinical Pharmacology·Jeffrey K Aronson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.